Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial

Clicks: 293
ID: 270323
2005
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Patients with moderately active ulcerative colitis treated with 4.8 g/day of mesalamine (800 mg tablet) are significantly more likely to achieve overall improvement at 6 wk compared to patients treated with 2.4 g/day.
Reference Key
sb2005thedelayed-release Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Hanauer SB;Sandborn WJ;Kornbluth A;Katz S;Safdi M;Woogen S;Regalli G;Yeh C;Smith-Hall N;Ajayi F;;
Journal the american journal of gastroenterology
Year 2005
DOI
DOI not found
URL
https://www.pubmed.gov/16279903/
Keywords
Administration National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine safety treatment outcome research support non-u.s. gov't adult female male adolescent aged middle aged Recurrence Remission Induction Comparative Study Randomized Controlled Trial Double-Blind Method Multicenter Study follow-up studies placebos Colitis Ulcerative / drug therapy* oral anti-inflammatory agents non-steroidal / adverse effects william j sandborn delayed-action preparations pmid:16279903 doi:10.1111/j.1572-0241.2005.00248.x stephen b hanauer funmilay ajayi non-steroidal / administration & dosage* non-steroidal / blood ulcerative / classification mesalamine / administration & dosage* mesalamine / adverse effects mesalamine / blood

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.